EGFR and colorectal carcinoma: One study of 25 CRC PDXs reported that a 147-gene RAS pathway transcriptomic signature significantly outperformed EGFR expression in predicting cetuximab response (31), supporting the development of multigene mRNA expression signatures as predictive biomarkers for therapy responses.